Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer
Squamous cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, about 400,000 persons die from squamous-cell lung cancer around the world, and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2013-12-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2013.12.10 |
| _version_ | 1828433929149874176 |
|---|---|
| author | Li MA Shucai ZHANG |
| author_facet | Li MA Shucai ZHANG |
| author_sort | Li MA |
| collection | DOAJ |
| description | Squamous cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, about 400,000 persons die from squamous-cell lung cancer around the world, and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit from major advances in the development of targeted therapeutics such as epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors that show exquisite activity in lungadenocarcinomas with EGFR mutations or echinoderm microtubule associated protein like-4 (EML4)-ALK fusions, respectively. Major efforts have been launched to characterize the genomes of squamous-cell lung cancers. Among the new results emanating from these efforts are amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, the discoidin domain receptor 2 (DDR2) gene mutation as potential novel targets for the treatment of SQCLCs. Researchers find that there are many specific molecular targeted genes in the genome of squamous-cell lung cancer patients. These changes play a vital role in cell cycle regulation, oxidative stress, cell apoptosis, squamous epithelium differentiation, may be the candidate targeted moleculars in SQCLCs. Here, we provide a review on these discoveries and their implications for clinical trials in squamous-cell lungcancer assessing the value of novel therapeutics addressing these targets. |
| first_indexed | 2024-12-10T18:42:52Z |
| format | Article |
| id | doaj.art-4fe172bb3f7c4f1ab0f8c4f0ce2e78cb |
| institution | Directory Open Access Journal |
| issn | 1009-3419 |
| language | zho |
| last_indexed | 2024-12-10T18:42:52Z |
| publishDate | 2013-12-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-4fe172bb3f7c4f1ab0f8c4f0ce2e78cb2022-12-22T01:37:36ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34192013-12-01161267167510.3779/j.issn.1009-3419.2013.12.10Advances of Molecular Targeted Therapy in Squamous Cell Lung CancerLi MA0Shucai ZHANG1Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University,
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, ChinaDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University,
Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, ChinaSquamous cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, about 400,000 persons die from squamous-cell lung cancer around the world, and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit from major advances in the development of targeted therapeutics such as epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors that show exquisite activity in lungadenocarcinomas with EGFR mutations or echinoderm microtubule associated protein like-4 (EML4)-ALK fusions, respectively. Major efforts have been launched to characterize the genomes of squamous-cell lung cancers. Among the new results emanating from these efforts are amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, the discoidin domain receptor 2 (DDR2) gene mutation as potential novel targets for the treatment of SQCLCs. Researchers find that there are many specific molecular targeted genes in the genome of squamous-cell lung cancer patients. These changes play a vital role in cell cycle regulation, oxidative stress, cell apoptosis, squamous epithelium differentiation, may be the candidate targeted moleculars in SQCLCs. Here, we provide a review on these discoveries and their implications for clinical trials in squamous-cell lungcancer assessing the value of novel therapeutics addressing these targets.http://dx.doi.org/10.3779/j.issn.1009-3419.2013.12.10Lung neoplasmSquamous-cell cancerTargeted therapy |
| spellingShingle | Li MA Shucai ZHANG Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer Chinese Journal of Lung Cancer Lung neoplasm Squamous-cell cancer Targeted therapy |
| title | Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer |
| title_full | Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer |
| title_fullStr | Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer |
| title_full_unstemmed | Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer |
| title_short | Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer |
| title_sort | advances of molecular targeted therapy in squamous cell lung cancer |
| topic | Lung neoplasm Squamous-cell cancer Targeted therapy |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2013.12.10 |
| work_keys_str_mv | AT lima advancesofmoleculartargetedtherapyinsquamouscelllungcancer AT shucaizhang advancesofmoleculartargetedtherapyinsquamouscelllungcancer |